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Severe hypoglycemia, defined as low
blood glucose requiring assistance for re-
covery, is arguably the most dangerous
complication of type 1 diabetes as it can
result in permanent cognitive impairment,
seizure, coma, accidents, and death (1,2).
Since the Diabetes Control and Complica-
tions Trial (DCCT) demonstrated that in-
tensive intervention to normalize glucose
prevents long-term complications but at the
price of a threefold increase in the rate of
severe hypoglycemia (3), hypoglycemia has
been recognized as the major limitation to
achieving tight glycemic control. Severe
hypoglycemia remains prevalent among
adults with type 1 diabetes, ranging from
;1.4% per year in the DCCT/EDIC (Epi-
demiology of Diabetes Interventions and
Complications) follow-up cohort (4) to;8%
in the T1D Exchange clinic registry (5).
One the greatest risk factors for severe
hypoglycemia is impaired awareness of
hypoglycemia (6),which increases risk up
to sixfold (7,8). Hypoglycemia unaware-
ness results from deficient counterregu-
lation (9), where falling glucose fails to
activate the autonomic nervous system
to produce neuroglycopenic symptoms
that normally help patients identify and
respond to episodes (i.e., sweating, pal-
pitations, hunger) (2). An estimated 20–
25% of adults with type 1 diabetes have
impaired hypoglycemia awareness (8),
which increases to more than 50% after
25 years of disease duration (10).
Screening for hypoglycemia unaware-
ness to identify patients at increased risk
of severe hypoglycemic events should
be part of routine diabetes care. Self-
identified impairment in awareness tends
to agreewith clinical evaluation (11). There-
fore, hypoglycemia unawareness can be
easily and effectively screened using mult-
iple, self-administered methods (11). These
range from single questions (i.e., “Do you
knowwhen your hypos are coming?” [7]
and “Can you feel when you are low?”
[12]) to longer assessments character-
izing hypoglycemia exposure and the
glycemic threshold for symptomatic re-
sponse, as in the 8-item Clarke question-
naire (11), and problematic hypoglycemia
with unawareness during wake and asleep,
as in the recently developed 33-item
Hypoglycaemia Awareness Questionnaire
(HypoA-Q) (13).
Interventions for hypoglycemia un-
awareness include a range of behavioral
andmedical options. Avoiding hypoglycemia
for at least several weeks may partially
reverse hypoglycemia unawareness and
reduce risk of future episodes (1). There-
fore, patients with hypoglycemia and
unawareness may be advised to raise
their glycemic and HbA1c targets (1,2).
Diabetes technology can play a role,
including continuous subcutaneous in-
sulin infusion (CSII) to optimize insulin
delivery, continuous glucose monitoring
(CGM) to give technological awareness
in the absence of symptoms (14), or the
combination of the two in newer sensor-
augmented insulin pumps with auto-
mated low-glucose suspend to prevent
hypoglycemia (14). For patients who are
refractory to medical treatment, human
islet cell transplantation has been shown
to mitigate severe hypoglycemia over
2 years (15), although this approach
carries additional risks, expenses, and
uncertain long-term benefit (16).
Aside from medical management,
structured or hypoglycemia-specific ed-
ucation programs that aim to prevent
hypoglycemia are recommended for all
patients with severe hypoglycemia or
hypoglycemia unawareness (14). In ran-
domized trials, psychoeducational pro-
grams that incorporate increased education,
identification of personal risk factors,
and behavior change support have im-
proved hypoglycemia unawareness and
reduced the incidence of both nonsevere
and severe hypoglycemia over short
periods of follow-up (17,18) and extending
up to 1 year (19).
The study by Little et al. (20) in this is-
sue of Diabetes Care is an elegant addi-
tion to existing data on the potential of
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psychoeducational intervention for this
high-risk population. Previously, the au-
thors reported findings at the close of the
HypoCOMPaSS trial, a 6-month 2 3 2 fac-
torial randomized trial to assess the ef-
fects of an intensive structured education
approach to hypoglycemia avoidance,
improved hypoglycemia awareness, and
prevention of recurrent severe hypogly-
cemia without worsening overall glycemic
control in adults with type 1 diabetes and
impaired hypoglycemia awareness (21).
The intervention emphasized four points of
hypoglycemiad1) never delay hypoglyce-
mia treatment, 2) recognize personalized
times of increased risk, 3) detect subtle
symptoms, and 4) confirm low glucose
levels through regular self-monitoringd
as well as advice on adjusting insulin dose
around blood glucose, carbohydrate intake,
and activity levels (21). In addition, each
randomization subgroup received education
tailored for technical aspects of their re-
spective insulin administration and glucose
monitoringmodality (21). Intervention bene-
fits were seen among those randomized to
CSII and multiple daily injections (MDI) and
among those randomized to adjuvant real-
time CGM and conventional self-monitoring
of blood glucose (SMBG) (21). At the end of
the 6-month intervention, the participants
returned to routine clinical care with data
collection every 6 months over 24 months
(20).While participants were able to change
insulin delivery regimen after the interven-
tionended, theCGMversusSMBGrandom-
ization assignment continued throughout
follow-up (20). The benefits in terms of
hypoglycemia awareness, reduced severe
hypoglycemia, and improvements in pa-
tient reported outcomes were sustained.
Finally, HbA1c improved over follow-up (20).
Although statistical power was limited for
subgroup comparisons, there were no sig-
nificant differences in outcomes between
randomized assignments (CSII vs. MDI or
SMBG vs. CGM) (20).
The trial included individuals with an
increased risk for severe hypoglycemia
(Gold score $4) (21), which reflects the
relevant population for the specific inter-
vention but limits generalizability to all
individuals with type 1 diabetes. Universal
screening guidelines may, in the future,
help to establish an evidence-based
threshold above which intervention is
warranted and maximally beneficial.
Moreover, all participants attended a
single 1- to 3-h education session focused
on avoiding hypoglycemia while main-
taining overall glycemic control thatwas
prior to randomization. The facilitated
discussion was led by a trained research
fellow or clinical provider (21). Although
the intervention was only implemented
in five U.K. tertiary referral diabetes
centers, the magnitude and durability
of effect reported by Little et al. (21)
suggests that dissemination and imple-
mentation efforts toward avoiding se-
vere hypoglycemia should have defined
curricula and engage multiple members
of the care team to promote ongoing
education, especially clinic- or commu-
nity-based certified diabetes educators.
A major strength is the study design
itself, including a long follow-up period
during which patients were seen in rou-
tine care, longitudinal extension of the
original 23 2 factorial design, and the in-
tegration of patient-oriented outcomes
alongsidebiochemical ones to characterize
intervention effect. The protocol-specified
flexibility in insulin regimen provides new
data to challenge the assumption that
reducing risk of severe hypoglycemia op-
timally requires insulin pump therapy as
suggested in observational cohorts (4).
Although current standards for care em-
phasize that CGM may be a useful tool in
those with hypoglycemia unawareness
(1,14), retention of the CGM versus
SMBG randomization in the current study
adds to a mixed literature on unique ad-
vantages of CGM for the incidence of se-
vere hypoglycemia (22,23). This article
offers insight into the durability of risk
reduction methods among patients who
are less inclined to adopt new technol-
ogy and may lend flexibility to clinical
care paradigm for these patients in the
future.
Given that the presence of hypogly-
cemia unawareness increases the risk of
severe hypoglycemia, which is the stron-
gest predictor of a future episode (2,4),
the implication that intervention can
break the life-threatening and trauma-
tizing cycle of hypoglycemia unaware-
ness and severe hypoglycemia cannot be
overstated. This new evidence of dura-
bility of effect across treatment regimen
without increasing the risk for long-term
complications creates an imperative for
action. In combinationwith existing screen-
ing tools and a body of literature investi-
gating novel interventions for hypoglycemia
unawareness, these results make the ap-
proach of screening, recognition, and inter-
vention very compelling as not only a best
practice but something that should be in-
corporated in universal guidelines on dia-
betes care, particularly for individuals with
type 1 diabetes (Fig. 1).
Little et al. (20) bring hypoglycemia to
the forefront of a larger conversation.
Figure 1—An overview of tools, evidence, and future considerations aimed to prevent severe hypoglycemia.
Hyperglycemia is, after all, only part of
the puzzle in diabetes management. Long-
term complications are decreasing across
the population with improved interven-
tions and their implementation (24). To this
end, it is essential to shift our historical ob-
session with hyperglycemia and its long-
term complications to equally emphasize
the disabling, distressing, and potentially
fatal near-term complication of our treat-
ments, namely severe hypoglycemia. The
American Diabetes Association (ADA)
should assemble and expand current rec-
ommendations in the Standards of Medical
Care in Diabeteswith a dedicated chapter on
both low-cost and technologically driven as-
sessments for hypoglycemia unawareness
and the prevention of severe hypoglycemia.
The focus of such a chapter should be on
implementationwith an emphasis on individ-
ualization, patient autonomy, andoverall
well-being. The health care providers’ first
dictum is primum non noceredabove all,
do no harm. ADA must refocus our atten-
tion on severe hypoglycemia as an iatro-
genic and preventable complication of our
interventions.
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